{"ticker": {"uuid": "2a6f65e5-1771-4a10-b90e-9b8e1223008b", "symbol": "RHO", "name": "Roche Holding AG", "exchange": "GER", "country": "DE", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?", "summary": "Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS is a key development to weigh against the rest of our analysis. Our analysis turns up 1 warning sign for", "url": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-10-01T20:08:11+00:00", "published_display": "01 Oct 2026 20:08", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007797, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 14.4, "age_days": 5.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Pharma", "Regulation"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Can Roche\u2019s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?", "summary": "Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new tr", "url": "https://finance.yahoo.com/healthcare/articles/roche-latest-obesity-drug-results-195829767.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-latest-obesity-drug-results-195829767.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-28T19:55:35+00:00", "published_display": "28 Sep 2026 19:55", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.02239, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 30.4, "age_days": 8.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Obesity", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships", "summary": "Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and obesity, highlighting Roche's GLP-1/GIP pipeline ambitions. These new AI-driven alliances and CT-388 Ph", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-signed-200634247.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-signed-200634247.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-27T20:06:34+00:00", "published_display": "27 Sep 2026 20:06", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019512, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 26.5, "age_days": 9.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI", "Drug Discovery", "Healthcare", "Metabolic Disease", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Roche targets Novartis on IgAN market after Phase III win", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-targets-novartis-igan-market-170659944.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-targets-novartis-igan-market-170659944.html", "source_link_is_lookup": false, "source_name": "Clinical Trials Arena", "published_at": "2026-09-24T17:06:59+00:00", "published_display": "24 Sep 2026 17:06", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000575, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.2, "age_days": 12.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues", "summary": "Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current valuation story. Recent phase III successes with partners like MediLink and Ionis, along with regulatory", "url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rop-stock-looks-231434027.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rop-stock-looks-231434027.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-23T23:14:34+00:00", "published_display": "23 Sep 2026 23:14", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Strategic partnership"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000445, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Pharma", "Share Price", "Shareholder", "Valuation"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?", "summary": "Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than fading. Capitalize on the momentum around Roche Holding and this latest clinical win by scanning a hand", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-undervalued-191416807.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-undervalued-191416807.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-23T19:14:16+00:00", "published_display": "23 Sep 2026 19:14", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Positive valuation view"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000567, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Dividends", "Intrinsic Value", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about 1.0% to $55.11. At that price, Roche trades 33.15% above its $41.39 GF Value. Investors are paying a premium even as this drug's longer-term benefits remain unproven. Warning! GuruFocus has detected 7 Warning Signs with RHHBY. Is RHHBY fairly valued? Test your thesis with our free DCF calculator.RHHBY GF Valu", "url": "https://finance.yahoo.com/healthcare/articles/roche-drops-phase-3-kidney-180621581.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-drops-phase-3-kidney-180621581.html", "source_link_is_lookup": false, "source_name": "GuruFocus.com", "published_at": "2026-09-23T18:06:21+00:00", "published_display": "23 Sep 2026 18:06", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00045, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche, Ionis RNA drug scores in kidney disease study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-ionis-rna-drug-scores-162156688.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-ionis-rna-drug-scores-162156688.html", "source_link_is_lookup": false, "source_name": "BioPharma Dive", "published_at": "2026-09-23T16:21:56+00:00", "published_display": "23 Sep 2026 16:21", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000402, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-sefaxersen-meets-primary-endpoint-101722025.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-sefaxersen-meets-primary-endpoint-101722025.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-23T10:17:22+00:00", "published_display": "23 Sep 2026 10:17", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000369, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.8, "age_days": 14.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share", "summary": "Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Therapeutic Drug Monitoring - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global market for Therapeutic Drug Monitoring was estimated at US$1.5 Billion in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 8.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of mar", "url": "https://finance.yahoo.com/healthcare/articles/capitalize-therapeutic-drug-monitoring-shift-081100417.html", "source_link": "https://finance.yahoo.com/healthcare/articles/capitalize-therapeutic-drug-monitoring-shift-081100417.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T08:11:00+00:00", "published_display": "23 Sep 2026 08:11", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011665, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 14.2, "age_days": 14.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI Software", "Chronic Disease", "Healthcare", "Market Research Reports", "Personalized Medicine", "Pharmacogenomics"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-roche-kidney-disease-075301108.html", "source_link": "https://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-roche-kidney-disease-075301108.html", "source_link_is_lookup": false, "source_name": "MT Newswires", "published_at": "2026-09-23T07:53:01+00:00", "published_display": "23 Sep 2026 07:53", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000356, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.8, "age_days": 14.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease", "summary": "", "url": "https://finance.yahoo.com/m/0319ea2d-d8e9-3fe9-bb12-9bb5c10f40f1/roche-drug-candidate-hits.html", "source_link": "https://finance.yahoo.com/m/0319ea2d-d8e9-3fe9-bb12-9bb5c10f40f1/roche-drug-candidate-hits.html", "source_link_is_lookup": false, "source_name": "The Wall Street Journal", "published_at": "2026-09-23T06:11:00+00:00", "published_display": "23 Sep 2026 06:11", "source_kind": "editorial_wire", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003663, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 3.8, "age_days": 14.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Positive interim data shows Roche\u2019s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)", "summary": "F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1 IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation2-4 Interim data will be presented at an upcom", "url": "https://finance.yahoo.com/healthcare/articles/positive-interim-data-shows-roche-051500868.html", "source_link": "https://finance.yahoo.com/healthcare/articles/positive-interim-data-shows-roche-051500868.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T05:15:00+00:00", "published_display": "23 Sep 2026 05:15", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000529, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "Low", "evidence_strength": 26, "duplicate_count": 2, "topics": ["Autoimmune Disease", "Biotech", "Clinical Trials", "Kidney Disease", "Nephrology", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "Change in Roche\u2019s Board of Directors", "summary": "F. Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: \"I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe's intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen our Board.\" About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare", "url": "https://finance.yahoo.com/healthcare/articles/change-roche-board-directors-050000145.html", "source_link": "https://finance.yahoo.com/healthcare/articles/change-roche-board-directors-050000145.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T05:00:00+00:00", "published_display": "23 Sep 2026 05:00", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000387, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Healthcare", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study", "summary": "Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight. The encouraging results strengthen Roche's prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market. Year to date, shares of Roche have risen 9.8% compared with the industry's rise of 7%.Zacks Investment Research Ima", "url": "https://finance.yahoo.com/healthcare/articles/roches-enicepatide-shows-weight-loss-193200876.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roches-enicepatide-shows-weight-loss-193200876.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-22T19:32:00+00:00", "published_display": "22 Sep 2026 19:32", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.022003, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 23.5, "age_days": 14.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Diabetes", "Obesity", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial", "summary": "", "url": "https://finance.yahoo.com/m/8e29ad97-b35d-305a-a479-a3a05dffe66f/roche-says-drug-helped.html", "source_link": "https://finance.yahoo.com/m/8e29ad97-b35d-305a-a479-a3a05dffe66f/roche-says-drug-helped.html", "source_link_is_lookup": false, "source_name": "The Wall Street Journal", "published_at": "2026-09-22T05:32:00+00:00", "published_display": "22 Sep 2026 05:32", "source_kind": "editorial_wire", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000553, "evidence_share": 2.6, "evidence_share_display": "2.6", "freshness_pct": 0.5, "age_days": 15.2, "influence_label": "Low", "evidence_strength": 26, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity", "summary": "F. Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of \u22646.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%) At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau Enicepatide demonstr", "url": "https://finance.yahoo.com/healthcare/articles/ad-hoc-announcement-pursuant-art-050000193.html", "source_link": "https://finance.yahoo.com/healthcare/articles/ad-hoc-announcement-pursuant-art-050000193.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-22T05:00:00+00:00", "published_display": "22 Sep 2026 05:00", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013531, "evidence_share": 62.8, "evidence_share_display": "62.8", "freshness_pct": 12.1, "age_days": 15.2, "influence_label": "Medium", "evidence_strength": 41, "duplicate_count": 1, "topics": ["Biotechnology", "Cardiovascular Disease", "Clinical Trials", "Glp 1 Receptor Agonist", "Obesity", "Shareholder"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "European Commission approves Roche\u2019s Susvimo\u00ae for the treatment of neovascular age-related macular degeneration (nAMD)", "summary": "F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3 Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2 nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European", "url": "https://finance.yahoo.com/healthcare/articles/european-commission-approves-roche-susvimo-154500005.html", "source_link": "https://finance.yahoo.com/healthcare/articles/european-commission-approves-roche-susvimo-154500005.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-21T15:45:00+00:00", "published_display": "21 Sep 2026 15:45", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000463, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 0.4, "age_days": 15.8, "influence_label": "Medium", "evidence_strength": 38, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Ophthalmology", "Pharma", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "CHMP recommends EU approval of Roche\u2019s Ocrevus for children and adolescents with relapsing multiple sclerosis", "summary": "F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1 Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) ", "url": "https://finance.yahoo.com/healthcare/articles/chmp-recommends-eu-approval-roche-104500076.html", "source_link": "https://finance.yahoo.com/healthcare/articles/chmp-recommends-eu-approval-roche-104500076.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-18T10:45:00+00:00", "published_display": "18 Sep 2026 10:45", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.014437, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 15.3, "age_days": 19.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Neurology", "Pharma", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche agrees to $1bn deal with Dualitas for bispecific antibody research", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-agrees-1bn-deal-dualitas-092924132.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-agrees-1bn-deal-dualitas-092924132.html", "source_link_is_lookup": false, "source_name": "Pharmaceutical Technology", "published_at": "2026-09-18T09:29:24+00:00", "published_display": "18 Sep 2026 09:29", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009917, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 15.2, "age_days": 19.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases", "summary": "F. Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon Base", "url": "https://finance.yahoo.com/healthcare/articles/roche-announces-grand-opening-innovation-183000672.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-announces-grand-opening-innovation-183000672.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-17T18:30:00+00:00", "published_display": "17 Sep 2026 18:30", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.9e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Drug Discovery", "Healthcare", "Innovation", "Life Sciences", "R D", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center", "summary": "Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon SOUTH SAN FRANCISCO, Calif., September 17, 2026--(BU", "url": "https://finance.yahoo.com/healthcare/articles/genentech-roche-announce-grand-opening-183000263.html", "source_link": "https://finance.yahoo.com/healthcare/articles/genentech-roche-announce-grand-opening-183000263.html", "source_link_is_lookup": false, "source_name": "Business Wire", "published_at": "2026-09-17T18:30:00+00:00", "published_display": "17 Sep 2026 18:30", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.5e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI", "Biotech", "Data Science", "Innovation", "R D"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma", "summary": "Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio's label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for Lunsumio and lenalidomide signals a broader story investors should weigh beyond this single trial update.", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-phase-151123658.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-phase-151123658.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-17T15:11:23+00:00", "published_display": "17 Sep 2026 15:11", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4.9e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Oncology", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-genentech-reports-positive-phase-142556275.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-genentech-reports-positive-phase-142556275.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-17T14:25:56+00:00", "published_display": "17 Sep 2026 14:25", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006329, "evidence_share": 29.4, "evidence_share_display": "29.4", "freshness_pct": 6.4, "age_days": 19.8, "influence_label": "Low", "evidence_strength": 33, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Roche, Dualitas team up to find bispecific drugs for immune diseases", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-dualitas-team-bispecific-drugs-060000560.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-dualitas-team-bispecific-drugs-060000560.html", "source_link_is_lookup": false, "source_name": "BioPharma Dive", "published_at": "2026-09-17T06:00:00+00:00", "published_display": "17 Sep 2026 06:00", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 59, "tone_signals": ["Strategic partnership"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7.2e-05, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 0.1, "age_days": 20.2, "influence_label": "Low", "evidence_strength": 29, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Roche\u2019s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study", "summary": "Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health authorities and presented at an upcoming medical meeting SOUTH SAN FRANCISCO, Calif., September 17, 202", "url": "https://finance.yahoo.com/healthcare/articles/roche-lunsumio-based-regimen-significantly-050000374.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-lunsumio-based-regimen-significantly-050000374.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-17T05:00:00+00:00", "published_display": "17 Sep 2026 05:00", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.9e-05, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 0.1, "age_days": 20.2, "influence_label": "Low", "evidence_strength": 28, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Healthcare", "Hematology Oncology", "Lymphoma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "Roche\u2019s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer", "summary": "F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink's proprietary TMALIN\u00ae platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, ", "url": "https://finance.yahoo.com/healthcare/articles/roche-collaborator-medilink-announces-phase-000000583.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-collaborator-medilink-announces-phase-000000583.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-13T00:00:00+00:00", "published_display": "13 Sep 2026 00:00", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.1e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 24.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Lung Cancer", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder", "summary": "Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Jan. 10, 2027. MOGAD is a rare autoimmune disease of the central nervous system that can cause unpredictable attacks affecting the optic nerves, spinal cord or brain. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD", "url": "https://finance.yahoo.com/healthcare/articles/roche-gets-fda-priority-tag-154200251.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-gets-fda-priority-tag-154200251.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-10T15:42:00+00:00", "published_display": "10 Sep 2026 15:42", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006869, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 7.1, "age_days": 26.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings Per Share", "Fda Approval"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Genentech Gets FDA Priority Review for Enspryng in MOGAD", "summary": "", "url": "https://finance.yahoo.com/m/685827c8-e9f0-32f6-9ad6-a55aabfd1dac/roche%E2%80%99s-genentech-gets-fda.html", "source_link": "https://finance.yahoo.com/m/685827c8-e9f0-32f6-9ad6-a55aabfd1dac/roche%E2%80%99s-genentech-gets-fda.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-10T14:35:30+00:00", "published_display": "10 Sep 2026 14:35", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Veterinary Diagnostic Markets Report Now Available \u2014 See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030", "summary": "Company Logo 249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With Confidence Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, by Animal, by Application, by Place, by Product, and by Country 2026 to 2030\" report has been added to ResearchAndMarkets.com's offering. The Veterinary Diagnostics industry is on a strong growth path driven by fundamental shifting patterns in animal ownership and management. Learn all ", "url": "https://finance.yahoo.com/healthcare/articles/veterinary-diagnostic-markets-report-now-103800385.html", "source_link": "https://finance.yahoo.com/healthcare/articles/veterinary-diagnostic-markets-report-now-103800385.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-07T10:38:00+00:00", "published_display": "07 Sep 2026 10:38", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operating growth"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 30.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Animal Health", "Diagnostic Testing", "Market Research Reports", "Pet Care", "Veterinary Diagnostics", "Veterinary Medicine"], "evidence_basis": "", "score_included": true, "direction_included": false}], "by_tier": {"direct": [{"title": "What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?", "summary": "Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS is a key development to weigh against the rest of our analysis. Our analysis turns up 1 warning sign for", "url": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-10-01T20:08:11+00:00", "published_display": "01 Oct 2026 20:08", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "ROP.SW", "provider_symbols": ["RHO.ARCHIVE", "ROP.SW", "ROP.US"], "target_provider_symbol": "ROP.SW", "cross_listing": false, "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "0472ea52eadc66dd4d06df71713f5344eef7b86b07fc521d9003a6ddb5d34334", "target_scope": "What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS? Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": 0.105, "relevance_score": 0.795492, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007797, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 14.4, "age_days": 5.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Pharma", "Regulation"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Can Roche\u2019s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?", "summary": "Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new tr", "url": "https://finance.yahoo.com/healthcare/articles/roche-latest-obesity-drug-results-195829767.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-latest-obesity-drug-results-195829767.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-28T19:55:35+00:00", "published_display": "28 Sep 2026 19:55", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "ROP.SW", "provider_symbols": ["AMGN.US", "AZN.US", "LLY.US", "NVO.US", "RHO.ARCHIVE", "ROP.SW"], "target_provider_symbol": "ROP.SW", "cross_listing": false, "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "498fffe97f60d4ef292ca9449cd4281c657e5ac4cdb319bb6a0ad56f86e45cc8", "target_scope": "Can Roche\u2019s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk? Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control The results add another potentially important asset to Roche's efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.51, "provider_directional_mass": 0.149, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.02239, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 30.4, "age_days": 8.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Obesity", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships", "summary": "Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and obesity, highlighting Roche's GLP-1/GIP pipeline ambitions. These new AI-driven alliances and CT-388 Ph", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-signed-200634247.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-signed-200634247.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-27T20:06:34+00:00", "published_display": "27 Sep 2026 20:06", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "ROP.SW", "provider_symbols": ["RHHBY.US", "RHO.ARCHIVE", "ROP.SW", "ROP.US"], "target_provider_symbol": "ROP.SW", "cross_listing": false, "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "5f0d89b1f9d4feba7ec8033a11d3cb14145b5986ec483d5b83281a71590e455c", "target_scope": "Roche Holding (SWX:ROP) Signed New AI Drug Discovery Partnerships Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and obesity, highlighting Roche's GLP-1/GIP pipeline ambitions.", "durable_archive": true, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.51, "provider_directional_mass": 0.1249, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.019512, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 26.5, "age_days": 9.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI", "Drug Discovery", "Healthcare", "Metabolic Disease", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Roche targets Novartis on IgAN market after Phase III win", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-targets-novartis-igan-market-170659944.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-targets-novartis-igan-market-170659944.html", "source_link_is_lookup": false, "source_name": "Clinical Trials Arena", "published_at": "2026-09-24T17:06:59+00:00", "published_display": "24 Sep 2026 17:06", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["NVS", "RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Clinical Trials Arena"], "source_kind": "publisher", "story_key": "cf6809a9440eb4314fd1ca7aff027f5a076653e2b92a4b127ab176908aa6b73d", "target_scope": "Roche targets Novartis on IgAN market after Phase III win", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000575, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.2, "age_days": 12.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues", "summary": "Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current valuation story. Recent phase III successes with partners like MediLink and Ionis, along with regulatory", "url": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rop-stock-looks-231434027.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/roche-swx-rop-stock-looks-231434027.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-23T23:14:34+00:00", "published_display": "23 Sep 2026 23:14", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["RHHBF.US", "RHHBY.US", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "ROP", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "400a72d6d50ae1088c68764bb3be3b6f798dec23f94d205671b2fd8a58d132b4", "target_scope": "Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current valuation story.", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000445, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Pharma", "Share Price", "Shareholder", "Valuation"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?", "summary": "Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than fading. Capitalize on the momentum around Roche Holding and this latest clinical win by scanning a hand", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-undervalued-191416807.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-undervalued-191416807.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-23T19:14:16+00:00", "published_display": "23 Sep 2026 19:14", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["RHHBF.US", "RHHBY.US", "RHO.ARCHIVE", "RHO.DE", "ROP", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "df427ae1ae9162abe61ebe2a5efecc5bd2ace8fa7365a38e9a7b8527054d1191", "target_scope": "Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win? Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. Capitalize on the momentum around Roche Holding and this latest clinical win by scanning a hand", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.54, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 55, "tone_signals": ["Positive valuation view"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000567, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Dividends", "Intrinsic Value", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof", "summary": "This article first appeared on GuruFocus. Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. Its U.S. depositary receipts slipped about 1.0% to $55.11. At that price, Roche trades 33.15% above its $41.39 GF Value. Investors are paying a premium even as this drug's longer-term benefits remain unproven. Warning! GuruFocus has detected 7 Warning Signs with RHHBY. Is RHHBY fairly valued? Test your thesis with our free DCF calculator.RHHBY GF Valu", "url": "https://finance.yahoo.com/healthcare/articles/roche-drops-phase-3-kidney-180621581.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-drops-phase-3-kidney-180621581.html", "source_link_is_lookup": false, "source_name": "GuruFocus.com", "published_at": "2026-09-23T18:06:21+00:00", "published_display": "23 Sep 2026 18:06", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["NKT.CO", "NVS", "RHHBY", "RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GuruFocus.com", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "ce9af906cc8df3974dbf213942b1ae71b0e2a830a7d8cc0065760c450fb110b2", "target_scope": "Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof Roche Holding (RHHBY), the pharmaceuticals and diagnostics group, reported that its experimental kidney drug sefaxersen cut protein in patients' urine significantly more than a placebo in a Phase 3 trial. but Its U.S. depositary receipts slipped about 1.0% to $55.11. At that price, Roche trades 33.15% above its $41.39 GF Value.", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.9, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00045, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche, Ionis RNA drug scores in kidney disease study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-ionis-rna-drug-scores-162156688.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-ionis-rna-drug-scores-162156688.html", "source_link_is_lookup": false, "source_name": "BioPharma Dive", "published_at": "2026-09-23T16:21:56+00:00", "published_display": "23 Sep 2026 16:21", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["IONS", "NVS", "RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["BioPharma Dive"], "source_kind": "publisher", "story_key": "4e38e1969f7dba2d172a5956bda55db59e44ebfab8524fef9de21ab194b44c88", "target_scope": "Roche, Ionis RNA drug scores in kidney disease study", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000402, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.9, "age_days": 13.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-sefaxersen-meets-primary-endpoint-101722025.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-sefaxersen-meets-primary-endpoint-101722025.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-23T10:17:22+00:00", "published_display": "23 Sep 2026 10:17", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["InvestorsHub"], "source_kind": "publisher", "story_key": "1477d8955f70a407ea93bea7cd672e1983dd1d3bbdc58e6ca131f59e7bb7ffaa", "target_scope": "Roche\u2019s Sefaxersen Meets Primary Endpoint in Phase III Kidney Disease Trial", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000369, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.8, "age_days": 14.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share", "summary": "Company Logo Personalized medicine and chronic disease care are driving demand for TDM, with opportunities in consumables, automation, point-of-care devices, AI software and pharmacogenomics. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- \"Therapeutic Drug Monitoring - Global Strategic Business Report\" has been added to ResearchAndMarkets.com's offering. The global market for Therapeutic Drug Monitoring was estimated at US$1.5 Billion in 2025 and is projected to reach US$2.6 Billion by 2032, growing at a CAGR of 8.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of mar", "url": "https://finance.yahoo.com/healthcare/articles/capitalize-therapeutic-drug-monitoring-shift-081100417.html", "source_link": "https://finance.yahoo.com/healthcare/articles/capitalize-therapeutic-drug-monitoring-shift-081100417.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T08:11:00+00:00", "published_display": "23 Sep 2026 08:11", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["ABT", "ABT.US", "BIO", "BIO.US", "RHHBF.US", "RHO.ARCHIVE", "RHO.DE", "ROP.SW", "SHL.DE", "SHL.XETRA", "TMO", "TMO.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "7d8edbe44d3b0213d23206d5d617265ce588f4719daaadc74c78d4678846a6ba", "target_scope": "Capitalize on the Therapeutic Drug Monitoring Shift: Benchmark Roche, Abbott, Siemens Healthineers, Thermo Fisher and Bio-Rad to Accelerate Revenue and Defend Market Share", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.011665, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 14.2, "age_days": 14.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI Software", "Chronic Disease", "Healthcare", "Market Research Reports", "Personalized Medicine", "Pharmacogenomics"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-roche-kidney-disease-075301108.html", "source_link": "https://finance.yahoo.com/healthcare/articles/ionis-pharmaceuticals-roche-kidney-disease-075301108.html", "source_link_is_lookup": false, "source_name": "MT Newswires", "published_at": "2026-09-23T07:53:01+00:00", "published_display": "23 Sep 2026 07:53", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["IONS", "RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["MT Newswires"], "source_kind": "publisher", "story_key": "132965c785a31af712ce29f059614a9f5dba7db81a72ab311f8d1102f634e73a", "target_scope": "Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000356, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.8, "age_days": 14.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease", "summary": "", "url": "https://finance.yahoo.com/m/0319ea2d-d8e9-3fe9-bb12-9bb5c10f40f1/roche-drug-candidate-hits.html", "source_link": "https://finance.yahoo.com/m/0319ea2d-d8e9-3fe9-bb12-9bb5c10f40f1/roche-drug-candidate-hits.html", "source_link_is_lookup": false, "source_name": "The Wall Street Journal", "published_at": "2026-09-23T06:11:00+00:00", "published_display": "23 Sep 2026 06:11", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["The Wall Street Journal"], "source_kind": "editorial_wire", "story_key": "1e3206aaf353c8d828aa15edf17a867dfd1d89a55a07c63938aae412be47ad64", "target_scope": "Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003663, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 3.8, "age_days": 14.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Positive interim data shows Roche\u2019s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)", "summary": "F. Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1 IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation2-4 Interim data will be presented at an upcom", "url": "https://finance.yahoo.com/healthcare/articles/positive-interim-data-shows-roche-051500868.html", "source_link": "https://finance.yahoo.com/healthcare/articles/positive-interim-data-shows-roche-051500868.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T05:15:00+00:00", "published_display": "23 Sep 2026 05:15", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY", "RHHBY.US", "RHHVF", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG", "ROG.US", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "9de92394f7d50134fa1652742aecbd73971a3e7099f4345da9d7546595057db7", "target_scope": "Positive interim data shows Roche\u2019s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) Hoffmann-La Roche Ltd In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1 IgAN is a progressive kidney disease that is typically diagnosed in young adults and up to 50% of people progress to kidney failure within 20 years, requiring dialysis or transplantation2-4 Interim data will be presented at an upcom", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000529, "evidence_share": 2.5, "evidence_share_display": "2.5", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "Low", "evidence_strength": 26, "duplicate_count": 2, "topics": ["Autoimmune Disease", "Biotech", "Clinical Trials", "Kidney Disease", "Nephrology", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "Change in Roche\u2019s Board of Directors", "summary": "F. Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: \"I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe's intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen our Board.\" About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare", "url": "https://finance.yahoo.com/healthcare/articles/change-roche-board-directors-050000145.html", "source_link": "https://finance.yahoo.com/healthcare/articles/change-roche-board-directors-050000145.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-23T05:00:00+00:00", "published_display": "23 Sep 2026 05:00", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY", "RHHBY.US", "RHHVF", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG", "ROG.US", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "400732f2abe46790d7f979fd4f9ba82830ed0f69ac996dd104bb718c1205be77", "target_scope": "Change in Roche\u2019s Board of Directors Hoffmann-La Roche Ltd Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche's Annual General Meeting on March 9, 2027. Roche Chairman Severin Schwan: \"I am pleased that we have been able to propose Christophe Weber for election to the Board of Directors. Christophe's intimate knowledge of the healthcare industry and his broad leadership experience will further strengthen our Board.\" About Roche Roche (SIX: RO, ROP", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000387, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.7, "age_days": 14.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Healthcare", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study", "summary": "Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. Enicepatide met both primary endpoints at 48 weeks, delivering dose-dependent reductions in HbA1c and body weight. The encouraging results strengthen Roche's prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market. Year to date, shares of Roche have risen 9.8% compared with the industry's rise of 7%.Zacks Investment Research Ima", "url": "https://finance.yahoo.com/healthcare/articles/roches-enicepatide-shows-weight-loss-193200876.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roches-enicepatide-shows-weight-loss-193200876.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-22T19:32:00+00:00", "published_display": "22 Sep 2026 19:32", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["LLY", "LLY.US", "NVO", "NVO.US", "RHHBF", "RHHBF.US", "RHHBY.US", "RHO.ARCHIVE", "RHO.DE"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Zacks", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "e3ba258a723b00a482da2db760293cddb1e24bb5a0e7968d3546a515bcc3ed13", "target_scope": "Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study Roche RHHBY reported encouraging top-line results from a mid-stage study of enicepatide (CT-388), its investigational once-weekly dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes (T2D) and overweight or obesity. The encouraging results strengthen Roche's prospects of establishing a foothold in the rapidly expanding obesity and metabolic disease market. Year to date, shares of Roche have risen 9.8% compared with the industry's rise of 7%.Zacks Investment Research Ima", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.442, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.65, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.022003, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 23.5, "age_days": 14.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Diabetes", "Obesity", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial", "summary": "", "url": "https://finance.yahoo.com/m/8e29ad97-b35d-305a-a479-a3a05dffe66f/roche-says-drug-helped.html", "source_link": "https://finance.yahoo.com/m/8e29ad97-b35d-305a-a479-a3a05dffe66f/roche-says-drug-helped.html", "source_link_is_lookup": false, "source_name": "The Wall Street Journal", "published_at": "2026-09-22T05:32:00+00:00", "published_display": "22 Sep 2026 05:32", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["The Wall Street Journal"], "source_kind": "editorial_wire", "story_key": "753ea0ecc4d2af1073ed826f98bdfeb7348081bec6736b145bc53438b9243d6e", "target_scope": "Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000553, "evidence_share": 2.6, "evidence_share_display": "2.6", "freshness_pct": 0.5, "age_days": 15.2, "influence_label": "Low", "evidence_strength": 26, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity", "summary": "F. Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of \u22646.5% HbA1c, while 62% achieved normoglycemia (HbA1c < 5.7%) At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau Enicepatide demonstr", "url": "https://finance.yahoo.com/healthcare/articles/ad-hoc-announcement-pursuant-art-050000193.html", "source_link": "https://finance.yahoo.com/healthcare/articles/ad-hoc-announcement-pursuant-art-050000193.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-22T05:00:00+00:00", "published_display": "22 Sep 2026 05:00", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["RHHBF.US", "RHHBY.US", "RHHVF.US", "RHO.ARCHIVE", "RO.SW", "ROG.US", "ROP.SW"], "target_provider_symbol": "RO.SW", "cross_listing": false, "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "ecf4af2e886dd4f98c1bb127aa732d0ac14544c4f403d2777061d2f8d774882a", "target_scope": "53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity Hoffmann-La Roche Ltd At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycemic control In patients with poor baseline glycemic control (HbA1c >8.5%), enicepatide 24 mg led to an HbA1c reduction of 4.13% at 48 weeks By week 48, 90% of patients in the 24 mg enicepatide arm met the T2D glycemic target of \u22646.5% HbA1c,", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.5529999999999999, "provider_directional_mass": 0.139, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 63, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.013531, "evidence_share": 62.8, "evidence_share_display": "62.8", "freshness_pct": 12.1, "age_days": 15.2, "influence_label": "Medium", "evidence_strength": 41, "duplicate_count": 1, "topics": ["Biotechnology", "Cardiovascular Disease", "Clinical Trials", "Glp 1 Receptor Agonist", "Obesity", "Shareholder"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "European Commission approves Roche\u2019s Susvimo\u00ae for the treatment of neovascular age-related macular degeneration (nAMD)", "summary": "F. Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3 Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2 nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European", "url": "https://finance.yahoo.com/healthcare/articles/european-commission-approves-roche-susvimo-154500005.html", "source_link": "https://finance.yahoo.com/healthcare/articles/european-commission-approves-roche-susvimo-154500005.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-21T15:45:00+00:00", "published_display": "21 Sep 2026 15:45", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["307.US", "AMD.US", "RHHBF", "RHHBF.US", "RHHBY.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG", "ROG.US", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "4d0fab042f32d7d5b93a50ac1739af7481b660fecef9a63e43ff309721f4d47b", "target_scope": "European Commission approves Roche\u2019s Susvimo\u00ae for the treatment of neovascular age-related macular degeneration (nAMD) Hoffmann-La Roche Ltd By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD1-3 Susvimo helps people with nAMD maintain their vision with as few as two treatments per year1-3 Data from the Phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections2 nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.621, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.111, "sentiment": "positive", "sentiment_pct": 67, "tone_signals": ["Contract or approval won"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000463, "evidence_share": 2.1, "evidence_share_display": "2.1", "freshness_pct": 0.4, "age_days": 15.8, "influence_label": "Medium", "evidence_strength": 38, "duplicate_count": 1, "topics": ["Clinical Trials", "Fda Approval", "Ophthalmology", "Pharma", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "CHMP recommends EU approval of Roche\u2019s Ocrevus for children and adolescents with relapsing multiple sclerosis", "summary": "F. Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1 Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency's (EMA) ", "url": "https://finance.yahoo.com/healthcare/articles/chmp-recommends-eu-approval-roche-104500076.html", "source_link": "https://finance.yahoo.com/healthcare/articles/chmp-recommends-eu-approval-roche-104500076.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-18T10:45:00+00:00", "published_display": "18 Sep 2026 10:45", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "RO.SW", "provider_symbols": ["CIS.US", "RHHBF", "RHHBF.US", "RHHBY.US", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "RMS.US", "RO.SW", "ROG", "ROG.US", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.DE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "54477b37ec8801a15b6b7d9ce77dac85dde5dfa11e67a59d72b26327f6b98d47", "target_scope": "CHMP recommends EU approval of Roche\u2019s Ocrevus for children and adolescents with relapsing multiple sclerosis Hoffmann-La Roche Ltd Ocrevus addresses a critical need in paediatric neurology as the first high- efficacy anti-CD20 treatment option for people with MS as young as 10 years old In the Phase III OPERETTA 2 study, Ocrevus demonstrated non-inferiority in relapse control and superiority over fingolimod in suppressing brain lesions1 Safety in children and adolescents was aligned with the established safety profile of Ocrevus across more than 525,000 adult patients globally1 Basel, 18 September 2026 - Roche (SIX: RO, ROP", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.014437, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 15.3, "age_days": 19.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Neurology", "Pharma", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche agrees to $1bn deal with Dualitas for bispecific antibody research", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-agrees-1bn-deal-dualitas-092924132.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-agrees-1bn-deal-dualitas-092924132.html", "source_link_is_lookup": false, "source_name": "Pharmaceutical Technology", "published_at": "2026-09-18T09:29:24+00:00", "published_display": "18 Sep 2026 09:29", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Pharmaceutical Technology"], "source_kind": "publisher", "story_key": "15d94224ed43e7c271fd7faf392aa1681966e708bdf282d607aecb415cdd9e72", "target_scope": "Roche agrees to $1bn deal with Dualitas for bispecific antibody research", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009917, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 15.2, "age_days": 19.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases", "summary": "F. Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon Base", "url": "https://finance.yahoo.com/healthcare/articles/roche-announces-grand-opening-innovation-183000672.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-announces-grand-opening-innovation-183000672.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-17T18:30:00+00:00", "published_display": "17 Sep 2026 18:30", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY.US", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG", "ROG.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "139fe0275f8beb46509e9b2864076b7fdc9dec1effa5bca1aee6e9c394b1d053", "target_scope": "Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases Hoffmann-La Roche Ltd The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development It will expand Roche's and Genentech's presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs This is part of Roche and Genentech's USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon Base", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5.9e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Drug Discovery", "Healthcare", "Innovation", "Life Sciences", "R D", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center", "summary": "Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon SOUTH SAN FRANCISCO, Calif., September 17, 2026--(BU", "url": "https://finance.yahoo.com/healthcare/articles/genentech-roche-announce-grand-opening-183000263.html", "source_link": "https://finance.yahoo.com/healthcare/articles/genentech-roche-announce-grand-opening-183000263.html", "source_link_is_lookup": false, "source_name": "Business Wire", "published_at": "2026-09-17T18:30:00+00:00", "published_display": "17 Sep 2026 18:30", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RHO.DU", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Business Wire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "7f782f6b26936e29b56cfd76706ed841fc8bbb921d042626257219189d30caf7", "target_scope": "Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center Roche Genentech Innovation Center Boston strengthens its research presence in Boston, reflecting a long-term commitment to one of the world's leading life sciences hubs Research focuses on cardiovascular, renal and metabolic diseases leveraging artificial intelligence and data science to advance drug discovery and development Innovation Center is part of Roche and Genentech's $50 billion investment in U.S. manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina and Hillsboro, Oregon SOUTH SAN FRANCISCO, Calif., September 17, 2026--(BU", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.51, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.5e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["AI", "Biotech", "Data Science", "Innovation", "R D"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma", "summary": "Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio's label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for Lunsumio and lenalidomide signals a broader story investors should weigh beyond this single trial update.", "url": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-phase-151123658.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-holding-swx-rop-phase-151123658.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-17T15:11:23+00:00", "published_display": "17 Sep 2026 15:11", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["RHHBY.US", "RHO.ARCHIVE", "RHO.DE", "ROP", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "861de015b35eebd541152fded768649338be0a555a4f6ef2a8230276b0f2c186", "target_scope": "Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals.", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4.9e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Clinical Trials", "Oncology", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-genentech-reports-positive-phase-142556275.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-genentech-reports-positive-phase-142556275.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-17T14:25:56+00:00", "published_display": "17 Sep 2026 14:25", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["InvestorsHub"], "source_kind": "publisher", "story_key": "ebf3560ba49491252d144296153a7396c3ef43eb778e0994265ebee7988c4f33", "target_scope": "Roche\u2019s Genentech Reports Positive Phase III CELESTIMO Results for Lunsumio in Follicular Lymphoma", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006329, "evidence_share": 29.4, "evidence_share_display": "29.4", "freshness_pct": 6.4, "age_days": 19.8, "influence_label": "Low", "evidence_strength": 33, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Roche, Dualitas team up to find bispecific drugs for immune diseases", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/roche-dualitas-team-bispecific-drugs-060000560.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-dualitas-team-bispecific-drugs-060000560.html", "source_link_is_lookup": false, "source_name": "BioPharma Dive", "published_at": "2026-09-17T06:00:00+00:00", "published_display": "17 Sep 2026 06:00", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["BioPharma Dive"], "source_kind": "publisher", "story_key": "d0cdff7bd22de3cd2ab7a5d0beac5e6ac2acdba866bd065f29d19229633d34e6", "target_scope": "Roche, Dualitas team up to find bispecific drugs for immune diseases", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.601, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 59, "tone_signals": ["Strategic partnership"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 7.2e-05, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 0.1, "age_days": 20.2, "influence_label": "Low", "evidence_strength": 29, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Roche\u2019s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study", "summary": "Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment Data reinforce the potential of this Lunsumio-based regimen to improve clinical outcomes, while offering a tolerable safety profile, simple dosing schedule and outpatient administration Data will be submitted to health authorities and presented at an upcoming medical meeting SOUTH SAN FRANCISCO, Calif., September 17, 202", "url": "https://finance.yahoo.com/healthcare/articles/roche-lunsumio-based-regimen-significantly-050000374.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-lunsumio-based-regimen-significantly-050000374.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-17T05:00:00+00:00", "published_display": "17 Sep 2026 05:00", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "RO.SW", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY", "RHHBY.US", "RHHVF", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "a4cfca867952990b58975117215a503fb9e9aa0d41ce7f26c67a6856c4bc0547", "target_scope": "Roche\u2019s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.525, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 58, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.9e-05, "evidence_share": 0.3, "evidence_share_display": "0.3", "freshness_pct": 0.1, "age_days": 20.2, "influence_label": "Low", "evidence_strength": 28, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Healthcare", "Hematology Oncology", "Lymphoma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": true}, {"title": "Roche\u2019s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer", "summary": "F. Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink's proprietary TMALIN\u00ae platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, ", "url": "https://finance.yahoo.com/healthcare/articles/roche-collaborator-medilink-announces-phase-000000583.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-collaborator-medilink-announces-phase-000000583.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-13T00:00:00+00:00", "published_display": "13 Sep 2026 00:00", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "ROP.SW", "provider_symbols": ["RHHBF", "RHHBF.US", "RHHBY", "RHHBY.US", "RHHVF", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "RO.SW", "ROG.US", "ROP.SW", "ROP.US"], "target_provider_symbol": "RHO.DE", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "7c1b6690817c44a3627acbbcd61303f0f6225204902a375c8ca9b1e0443fde81", "target_scope": "Roche\u2019s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer Hoffmann-La Roche Ltd Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong,", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.1e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 24.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Lung Cancer", "Shareholder"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder", "summary": "Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Jan. 10, 2027. MOGAD is a rare autoimmune disease of the central nervous system that can cause unpredictable attacks affecting the optic nerves, spinal cord or brain. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD", "url": "https://finance.yahoo.com/healthcare/articles/roche-gets-fda-priority-tag-154200251.html", "source_link": "https://finance.yahoo.com/healthcare/articles/roche-gets-fda-priority-tag-154200251.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-10T15:42:00+00:00", "published_display": "10 Sep 2026 15:42", "provider": "archive", "providers": ["archive", "eodhd"], "provider_symbol": "ROP.SW", "provider_symbols": ["ANIK.US", "PGEN.US", "RGEN.US", "RHHBF", "RHHBF.US", "RHHBY", "RHHBY.US", "RHHVF", "RHHVF.US", "RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["Zacks", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "ce109d123f6eeb259c94d92b20ad4911ff7e78520f19d12a00895f0a87c4a390", "target_scope": "Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006869, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 7.1, "age_days": 26.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Earnings Per Share", "Fda Approval"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Roche\u2019s Genentech Gets FDA Priority Review for Enspryng in MOGAD", "summary": "", "url": "https://finance.yahoo.com/m/685827c8-e9f0-32f6-9ad6-a55aabfd1dac/roche%E2%80%99s-genentech-gets-fda.html", "source_link": "https://finance.yahoo.com/m/685827c8-e9f0-32f6-9ad6-a55aabfd1dac/roche%E2%80%99s-genentech-gets-fda.html", "source_link_is_lookup": false, "source_name": "InvestorsHub", "published_at": "2026-09-10T14:35:30+00:00", "published_display": "10 Sep 2026 14:35", "provider": "archive", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["RHO.ARCHIVE", "RHO.DE", "ROP.SW"], "target_provider_symbol": "RHO.ARCHIVE", "cross_listing": false, "source_names": ["InvestorsHub"], "source_kind": "publisher", "story_key": "d05ade422b766ddf93be51302c487e33ff44919521d7084c24c4a5086faeaa7b", "target_scope": "Roche\u2019s Genentech Gets FDA Priority Review for Enspryng in MOGAD", "durable_archive": true, "archive_provider": "yfinance", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Veterinary Diagnostic Markets Report Now Available \u2014 See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030", "summary": "Company Logo 249-Page Report Delivers Country-by-Country Forecasts Across 15 Markets, Competitive Profiles of 32 Companies, and the Investment-Grade Data You Need to Act With Confidence Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Veterinary Diagnostic Markets. Strategy & Trends with Forecasts by Assay Type, by Animal, by Application, by Place, by Product, and by Country 2026 to 2030\" report has been added to ResearchAndMarkets.com's offering. The Veterinary Diagnostics industry is on a strong growth path driven by fundamental shifting patterns in animal ownership and management. Learn all ", "url": "https://finance.yahoo.com/healthcare/articles/veterinary-diagnostic-markets-report-now-103800385.html", "source_link": "https://finance.yahoo.com/healthcare/articles/veterinary-diagnostic-markets-report-now-103800385.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-09-07T10:38:00+00:00", "published_display": "07 Sep 2026 10:38", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "ROP.SW", "provider_symbols": ["RHHBF.US", "RHHBY.US", "RHO.ARCHIVE", "ROP.SW", "TMO.US", "ZTS.US"], "target_provider_symbol": "ROP.SW", "cross_listing": false, "source_names": ["finance.yahoo.com"], "source_kind": "aggregator", "story_key": "1412d95ecf569913b3ae43f98188c1af4b277ae243eda2b088c01f566a3a2572", "target_scope": "See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030", "durable_archive": true, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.164, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 30.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Animal Health", "Diagnostic Testing", "Market Research Reports", "Pet Care", "Veterinary Diagnostics", "Veterinary Medicine"], "evidence_basis": "", "score_included": true, "direction_included": false}], "industry": [], "sector": []}, "total_fetched": 30, "total_unique": 30, "total_relevant": 30, "pipeline_health": {"status": "partial", "providers_attempted": 3, "providers_with_results": 1, "raw_articles": 115, "unique_stories": 88, "duplicates_removed": 27, "relevant_stories": 30, "matched_archive_stories": 28, "current_evidence": 7, "direct_evidence": 30, "archive_articles": 25, "durable_story_count": 30, "durable_evidence_used": true, "durable_collected_at": "2026-10-07T01:50:44.545156+00:00"}, "sentiment_summary": {"positive": 6, "negative": 1, "neutral": 23, "score": 50, "raw_score": 61, "total": 30, "evidence_count": 7, "effective_articles": 2.07, "information_mass": 0.022, "direct_story_count": 30, "directional_story_count": 7, "direct_source_count": 5, "industry_story_count": 0, "sector_story_count": 0, "story_count": 30, "source_count": 5, "source_concentration": 0.4837, "direct_share": 78, "dispersion": 4, "confidence": 14, "evidence_status": "provisional", "score_version": "evidence-v11", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-10-01T20:08:11+00:00", "label": "Early balanced news score", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 12.86, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 2.93, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.08, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.0, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.6, "count": 1}], "positive_events": 6, "negative_events": 1, "pipeline": {"status": "partial", "providers_attempted": 3, "providers_with_results": 1, "raw_articles": 115, "unique_stories": 88, "duplicates_removed": 27, "relevant_stories": 30, "matched_archive_stories": 28, "current_evidence": 7, "direct_evidence": 30, "archive_articles": 25, "durable_story_count": 30, "durable_evidence_used": true, "durable_collected_at": "2026-10-07T01:50:44.545156+00:00"}}, "market_context": {"has_market_context": true, "latest_close": 381.799988, "latest_week": "2026-10-02", "one_week_move": -3.7, "four_week_move": -1.2, "twelve_week_move": 3.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.243675, "market_dynamics_buy_signal": false, "relative_strength": 3.011254, "fair_value_gap": 12.8, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 57.5442, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.7% over one week, -1.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Early company-news score", "tone": "neutral", "classification": "provisional", "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 14, "badges": ["Provisional evidence"], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 8}, {"label": "finance.yahoo.com", "count": 5}, {"label": "Simply Wall St.", "count": 3}, {"label": "InvestorsHub", "count": 3}, {"label": "BioPharma Dive", "count": 2}, {"label": "The Wall Street Journal", "count": 2}, {"label": "Zacks", "count": 2}, {"label": "Clinical Trials Arena", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 30}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 5}, {"label": "Regulatory and legal", "count": 3}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Early balanced news score"}, {"label": "Evidence confidence", "value": "14/100", "tone": "neutral", "text": "2.07 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Early company-news score", "tone": "neutral", "text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "30", "tone": "positive", "text": "78% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "4/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.7% over one week, -1.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?"}], "updated_at": "2026-10-07T01:50:44.545156+00:00", "detail_intelligence": {"headline": "Early balanced news score", "summary": "30 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 50, "display": "50", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 14, "display": "14", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 78, "display": "78%", "tone": "positive", "note": "30 company stories"}, {"label": "Story agreement", "value": 96, "display": "96", "tone": "positive", "note": "4/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 0, "note": "0.022 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "5 independent publishers"}, {"label": "Company relevance", "value": 78, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 12, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 96, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 52, "note": "less reliance on one publisher"}], "influence": {"events": [{"label": "Earnings", "positive": 0.020003, "negative": 0.0, "count": 2, "positive_share": 92.1, "positive_width": 50.0, "negative_share": 0.0, "negative_width": 0.0}, {"label": "Market update", "positive": 0.0011539999999999999, "negative": 0.000563, "count": 5, "positive_share": 5.3, "positive_width": 2.885, "negative_share": 2.6, "negative_width": 1.407}], "sources": [{"label": "finance.yahoo.com", "weight": 0.013628, "count": 1, "share": 62.7}, {"label": "InvestorsHub", "weight": 0.006375, "count": 1, "share": 29.4}, {"label": "Company disclosures", "weight": 0.001081, "count": 3, "share": 5.0}, {"label": "The Wall Street Journal", "weight": 0.000563, "count": 1, "share": 2.6}, {"label": "BioPharma Dive", "weight": 7.3e-05, "count": 1, "share": 0.3}], "directional_count": 7, "retained_count": 30, "source_count": 5, "top_share": 62.7, "axis_max": 92.1}, "freshness": 12, "source_independence": 52, "timeline": [{"date": "2026-09-08", "label": "08 Sep", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-09", "label": "09 Sep", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-10", "label": "10 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-11", "label": "11 Sep", "count": 0, "score": null, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-12", "label": "12 Sep", "count": 0, "score": null, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-13", "label": "13 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 199.9, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-14", "label": "14 Sep", "count": 0, "score": null, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-15", "label": "15 Sep", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-16", "label": "16 Sep", "count": 0, "score": null, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-17", "label": "17 Sep", "count": 6, "score": 57, "tone": "neutral", "x": 326.3, "y": 122.3, "volume_height": 31.2, "volume_y": 234.8}, {"date": "2026-09-18", "label": "18 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 10.4, "volume_y": 255.6}, {"date": "2026-09-19", "label": "19 Sep", "count": 0, "score": null, "tone": "neutral", "x": 389.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-20", "label": "20 Sep", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-21", "label": "21 Sep", "count": 1, "score": 67, "tone": "positive", "x": 452.6, "y": 104.1, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-22", "label": "22 Sep", "count": 3, "score": 55, "tone": "neutral", "x": 484.2, "y": 125.9, "volume_height": 15.6, "volume_y": 250.4}, {"date": "2026-09-23", "label": "23 Sep", "count": 10, "score": 50, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-24", "label": "24 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-25", "label": "25 Sep", "count": 0, "score": null, "tone": "neutral", "x": 579.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-26", "label": "26 Sep", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-27", "label": "27 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 642.1, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-28", "label": "28 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-09-29", "label": "29 Sep", "count": 0, "score": null, "tone": "neutral", "x": 705.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-30", "label": "30 Sep", "count": 0, "score": null, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-01", "label": "01 Oct", "count": 1, "score": 53, "tone": "neutral", "x": 768.5, "y": 129.5, "volume_height": 5.2, "volume_y": 260.8}, {"date": "2026-10-02", "label": "02 Oct", "count": 0, "score": null, "tone": "neutral", "x": 800.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-03", "label": "03 Oct", "count": 0, "score": null, "tone": "neutral", "x": 831.7, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-04", "label": "04 Oct", "count": 0, "score": null, "tone": "neutral", "x": 863.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-05", "label": "05 Oct", "count": 0, "score": null, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-06", "label": "06 Oct", "count": 0, "score": null, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-07", "label": "07 Oct", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "105.2,135.0 199.9,135.0 326.3,122.3 357.9,135.0 452.6,104.1 484.2,125.9 515.8,135.0 547.4,135.0 642.1,135.0 673.7,135.0 768.5,129.5", "timeline_path": "M105.2,135.0 M199.9,135.0 M326.3,122.3 L357.9,135.0 M452.6,104.1 L484.2,125.9 L515.8,135.0 L547.4,135.0 M642.1,135.0 L673.7,135.0 M768.5,129.5", "timeline_has_signal": true, "timeline_start": "08 Sep", "timeline_mid": "23 Sep", "timeline_end": "07 Oct", "momentum": {"label": "Cooling", "tone": "neutral", "recent_score": null, "prior_score": 53, "delta": null, "recent_count": 0, "prior_count": 1, "volume_delta": -1, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 53, "delta": null, "latest_count": 0, "baseline_count": 1, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 0, "share": 0}, {"label": "4 to 7 days", "count": 1, "share": 3}, {"label": "8 to 14 days", "count": 8, "share": 27}, {"label": "15 to 21 days", "count": 17, "share": 57}, {"label": "22 to 30 days", "count": 4, "share": 13}], "source_profile": [{"label": "GlobeNewswire", "count": 8, "share": 27, "score": 50, "tone": "neutral"}, {"label": "finance.yahoo.com", "count": 5, "share": 17, "score": 53, "tone": "neutral"}, {"label": "InvestorsHub", "count": 3, "share": 10, "score": 57, "tone": "neutral"}, {"label": "Simply Wall St.", "count": 3, "share": 10, "score": 53, "tone": "neutral"}, {"label": "BioPharma Dive", "count": 2, "share": 7, "score": 51, "tone": "neutral"}, {"label": "The Wall Street Journal", "count": 2, "share": 7, "score": 49, "tone": "neutral"}, {"label": "Zacks", "count": 2, "share": 7, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Market update", "count": 20, "share": 67, "score": 53, "tone": "neutral"}, {"label": "Earnings", "count": 5, "share": 17, "score": 53, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 3, "share": 10, "score": 50, "tone": "neutral"}, {"label": "Analyst action", "count": 1, "share": 3, "score": 50, "tone": "neutral"}, {"label": "Deals and strategy", "count": 1, "share": 3, "score": 50, "tone": "neutral"}], "topics": [{"label": "Clinical Trials", "count": 14, "share": 47}, {"label": "Pharma", "count": 10, "share": 33}, {"label": "Biotech", "count": 9, "share": 30}, {"label": "Shareholder", "count": 7, "share": 23}, {"label": "Fda Approval", "count": 6, "share": 20}, {"label": "Healthcare", "count": 5, "share": 17}, {"label": "Obesity", "count": 3, "share": 10}, {"label": "R D", "count": 2, "share": 7}, {"label": "Oncology", "count": 2, "share": 7}, {"label": "Market Research Reports", "count": 2, "share": 7}], "supporting": [{"label": "Direct evidence", "text": "30 current stories are mapped specifically to RHO."}, {"label": "Source breadth", "text": "The score uses 5 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.022."}, {"label": "Confidence", "text": "Confidence is 14/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?", "summary": "Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority review. The filing covers fenebrutinib as an oral BTK inhibitor for both relapsing and primary progressive forms of multiple sclerosis. If approved, fenebrutinib could become the first high efficacy oral BTK inhibitor targeting both relapse control and disability progression in MS. The FDA's priority review for fenebrutinib in relapsing and primary progressive MS is a key development to weigh against the rest of our analysis. Our analysis turns up 1 warning sign for", "url": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link": "https://finance.yahoo.com/healthcare/articles/could-roche-holding-swx-rop-200811251.html", "source_link_is_lookup": false, "source_name": "finance.yahoo.com", "published_at": "2026-10-01T20:08:11+00:00", "published_display": "01 Oct 2026 20:08", "source_kind": "aggregator", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 53, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.007937, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 14.7, "age_days": 5.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Fda Approval", "Pharma", "Regulation"], "evidence_basis": "", "score_included": true, "direction_included": false}, "article_count": 30, "updated_at": "2026-10-07T01:50:44.545156+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 195.8, "label": "10 Apr 2026", "close": 354.799988, "index": 100.0}, {"x": 78.4, "y": 180.2, "label": "17 Apr 2026", "close": 360.600006, "index": 101.6}, {"x": 114.9, "y": 182.3, "label": "24 Apr 2026", "close": 359.799988, "index": 101.4}, {"x": 151.3, "y": 190.4, "label": "01 May 2026", "close": 356.799988, "index": 100.6}, {"x": 187.7, "y": 198.0, "label": "08 May 2026", "close": 354.0, "index": 99.8}, {"x": 224.2, "y": 175.9, "label": "15 May 2026", "close": 362.200012, "index": 102.1}, {"x": 260.6, "y": 150.0, "label": "22 May 2026", "close": 371.799988, "index": 104.8}, {"x": 297.0, "y": 159.1, "label": "29 May 2026", "close": 368.399994, "index": 103.8}, {"x": 333.5, "y": 174.3, "label": "05 Jun 2026", "close": 362.799988, "index": 102.3}, {"x": 369.9, "y": 176.4, "label": "12 Jun 2026", "close": 362.0, "index": 102.0}, {"x": 406.3, "y": 202.9, "label": "19 Jun 2026", "close": 352.200012, "index": 99.3}, {"x": 442.8, "y": 153.2, "label": "26 Jun 2026", "close": 370.600006, "index": 104.5}, {"x": 479.2, "y": 142.4, "label": "03 Jul 2026", "close": 374.600006, "index": 105.6}, {"x": 515.6, "y": 160.2, "label": "10 Jul 2026", "close": 368.0, "index": 103.7}, {"x": 552.0, "y": 161.8, "label": "17 Jul 2026", "close": 367.399994, "index": 103.6}, {"x": 588.5, "y": 106.3, "label": "24 Jul 2026", "close": 388.0, "index": 109.4}, {"x": 624.9, "y": 105.7, "label": "31 Jul 2026", "close": 388.200012, "index": 109.4}, {"x": 661.3, "y": 76.0, "label": "07 Aug 2026", "close": 399.200012, "index": 112.5}, {"x": 697.8, "y": 115.4, "label": "14 Aug 2026", "close": 384.600006, "index": 108.4}, {"x": 734.2, "y": 57.1, "label": "21 Aug 2026", "close": 406.200012, "index": 114.5}, {"x": 770.6, "y": 95.5, "label": "28 Aug 2026", "close": 392.0, "index": 110.5}, {"x": 807.1, "y": 110.0, "label": "04 Sep 2026", "close": 386.600006, "index": 109.0}, {"x": 843.5, "y": 146.2, "label": "11 Sep 2026", "close": 373.200012, "index": 105.2}, {"x": 879.9, "y": 110.6, "label": "18 Sep 2026", "close": 386.399994, "index": 108.9}, {"x": 916.4, "y": 83.6, "label": "25 Sep 2026", "close": 396.399994, "index": 111.7}, {"x": 952.8, "y": 123.0, "label": "02 Oct 2026", "close": 381.799988, "index": 107.6}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "tone": "neutral", "close": 370.600006, "label": "26 Jun 2026", "score": 50, "stories": 1, "raw_score": 50, "confidence": 0, "price_change": 5.2, "x": 448.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "tone": "neutral", "close": 374.600006, "label": "03 Jul 2026", "score": 50, "stories": 2, "raw_score": 50, "confidence": 0, "price_change": 1.1, "x": 484.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "tone": "neutral", "close": 368.0, "label": "10 Jul 2026", "score": 50, "stories": 3, "raw_score": 50, "confidence": 0, "price_change": -1.8, "x": 520.8, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "tone": "neutral", "close": 367.399994, "label": "17 Jul 2026", "score": 50, "stories": 3, "raw_score": 50, "confidence": 0, "price_change": -0.2, "x": 557.2, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "tone": "neutral", "close": 388.0, "label": "24 Jul 2026", "score": 54, "stories": 14, "raw_score": 66, "confidence": 32, "price_change": 5.6, "x": 593.7, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "tone": "neutral", "close": 388.200012, "label": "31 Jul 2026", "score": 54, "stories": 17, "raw_score": 67, "confidence": 29, "price_change": 0.1, "x": 630.1, "y": 122.6, "show_label": false, "label_y": 112.6}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "tone": "neutral", "close": 399.200012, "label": "07 Aug 2026", "score": 48, "stories": 26, "raw_score": 45, "confidence": 35, "price_change": 2.8, "x": 666.5, "y": 133.7, "show_label": true, "label_y": 123.69999999999999}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 384.600006, "label": "14 Aug 2026", "score": 55, "stories": 32, "raw_score": 63, "confidence": 32, "price_change": -3.7, "x": 703.0, "y": 120.8, "show_label": false, "label_y": 110.8}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 406.200012, "label": "21 Aug 2026", "score": 52, "stories": 30, "raw_score": 63, "confidence": 22, "price_change": 5.6, "x": 739.4, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 392.0, "label": "28 Aug 2026", "score": 55, "stories": 27, "raw_score": 67, "confidence": 33, "price_change": -3.5, "x": 775.8, "y": 120.8, "show_label": true, "label_y": 110.8}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "tone": "neutral", "close": 386.600006, "label": "04 Sep 2026", "score": 52, "stories": 22, "raw_score": 60, "confidence": 27, "price_change": -1.4, "x": 812.3, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "tone": "neutral", "close": 373.200012, "label": "11 Sep 2026", "score": 51, "stories": 18, "raw_score": 60, "confidence": 21, "price_change": -3.5, "x": 848.7, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "tone": "neutral", "close": 386.399994, "label": "18 Sep 2026", "score": 52, "stories": 26, "raw_score": 58, "confidence": 26, "price_change": 3.5, "x": 885.1, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "tone": "neutral", "close": 396.399994, "label": "25 Sep 2026", "score": 51, "stories": 36, "raw_score": 57, "confidence": 22, "price_change": 2.6, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-10-02T23:59:59.999Z", "date": "2026-10-02", "tone": "neutral", "close": 381.799988, "label": "02 Oct 2026", "score": 50, "stories": 34, "raw_score": 60, "confidence": 16, "price_change": -3.7, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,195.8 78.4,180.2 114.9,182.3 151.3,190.4 187.7,198.0 224.2,175.9 260.6,150.0 297.0,159.1 333.5,174.3 369.9,176.4 406.3,202.9 442.8,153.2 479.2,142.4 515.6,160.2 552.0,161.8 588.5,106.3 624.9,105.7 661.3,76.0 697.8,115.4 734.2,57.1 770.6,95.5 807.1,110.0 843.5,146.2 879.9,110.6 916.4,83.6 952.8,123.0", "sentiment_path": "448.0,130.0 484.4,130.0 520.8,130.0 557.2,130.0 593.7,122.6 630.1,122.6 666.5,133.7 703.0,120.8 739.4,126.3 775.8,120.8 812.3,126.3 848.7,128.2 885.1,126.3 921.6,128.2 958.0,130.0", "score_version": "evidence-v11", "price_change": 7.6, "sentiment_change": 0, "recent_pairs": [{"at": "2026-10-02T23:59:59.999Z", "date": "2026-10-02", "tone": "neutral", "close": 381.799988, "label": "02 Oct 2026", "score": 50, "stories": 34, "raw_score": 60, "confidence": 16, "price_change": -3.7, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "tone": "neutral", "close": 396.399994, "label": "25 Sep 2026", "score": 51, "stories": 36, "raw_score": 57, "confidence": 22, "price_change": 2.6, "x": 921.6, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "tone": "neutral", "close": 386.399994, "label": "18 Sep 2026", "score": 52, "stories": 26, "raw_score": 58, "confidence": 26, "price_change": 3.5, "x": 885.1, "y": 126.3, "show_label": true, "label_y": 116.3}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "tone": "neutral", "close": 373.200012, "label": "11 Sep 2026", "score": 51, "stories": 18, "raw_score": 60, "confidence": 21, "price_change": -3.5, "x": 848.7, "y": 128.2, "show_label": false, "label_y": 118.19999999999999}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "tone": "neutral", "close": 386.600006, "label": "04 Sep 2026", "score": 52, "stories": 22, "raw_score": 60, "confidence": 27, "price_change": -1.4, "x": 812.3, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "tone": "neutral", "close": 392.0, "label": "28 Aug 2026", "score": 55, "stories": 27, "raw_score": 67, "confidence": 33, "price_change": -3.5, "x": 775.8, "y": 120.8, "show_label": true, "label_y": 110.8}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "tone": "neutral", "close": 406.200012, "label": "21 Aug 2026", "score": 52, "stories": 30, "raw_score": 63, "confidence": 22, "price_change": 5.6, "x": 739.4, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "tone": "neutral", "close": 384.600006, "label": "14 Aug 2026", "score": 55, "stories": 32, "raw_score": 63, "confidence": 32, "price_change": -3.7, "x": 703.0, "y": 120.8, "show_label": false, "label_y": 110.8}], "reconstructed": true, "latest_close": 381.799988, "price_observations": 26, "sentiment_observations": 15, "sentiment_start_label": "26 Jun 2026", "sentiment_end_label": "02 Oct 2026", "sentiment_history_limited": false, "price_axis_high": 116.5, "price_axis_mid": 106.9, "price_axis_low": 97.3, "start_label": "10 Apr", "mid_label": "07 Jul", "end_label": "02 Oct", "live_score_version": "evidence-v11", "comparable_to_live": true}, "sentiment_history": [{"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v11", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start"}, {"tone": "neutral", "delta": 0, "label": "01 Jul 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "10 Jul 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "20 Jul 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "21 Jul 23:59", "score": 51, "height": 4, "articles": 6, "confidence": 29, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 29, "score_change_display": "+1"}, {"tone": "neutral", "delta": 1, "label": "22 Jul 23:59", "score": 51, "height": 4, "articles": 7, "confidence": 25, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0"}, {"tone": "neutral", "delta": 5, "label": "23 Jul 23:59", "score": 55, "height": 10, "articles": 11, "confidence": 35, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": 4, "reconstructed": true, "score_version": "evidence-v11", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+4"}, {"tone": "neutral", "delta": 4, "label": "24 Jul 23:59", "score": 54, "height": 8, "articles": 14, "confidence": 32, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "28 Jul 23:59", "score": 53, "height": 6, "articles": 15, "confidence": 26, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "29 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 24, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 4, "label": "31 Jul 23:59", "score": 54, "height": 8, "articles": 17, "confidence": 29, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+2"}, {"tone": "neutral", "delta": 3, "label": "04 Aug 23:59", "score": 53, "height": 6, "articles": 18, "confidence": 28, "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "05 Aug 23:59", "score": 53, "height": 6, "articles": 21, "confidence": 26, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": -4, "label": "06 Aug 23:59", "score": 46, "height": 8, "articles": 25, "confidence": 34, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": -7, "reconstructed": true, "score_version": "evidence-v11", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 8, "score_change_display": "-7"}, {"tone": "neutral", "delta": -2, "label": "07 Aug 23:59", "score": 48, "height": 4, "articles": 26, "confidence": 35, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+2"}, {"tone": "neutral", "delta": -2, "label": "09 Aug 23:59", "score": 48, "height": 4, "articles": 26, "confidence": 29, "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "+0"}, {"tone": "neutral", "delta": -2, "label": "10 Aug 23:59", "score": 48, "height": 4, "articles": 27, "confidence": 27, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 4, "label": "11 Aug 23:59", "score": 54, "height": 8, "articles": 29, "confidence": 34, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 7, "score_change_display": "+6"}, {"tone": "neutral", "delta": 6, "label": "12 Aug 23:59", "score": 56, "height": 12, "articles": 31, "confidence": 37, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+2"}, {"tone": "neutral", "delta": 5, "label": "13 Aug 23:59", "score": 55, "height": 10, "articles": 32, "confidence": 34, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "20 Aug 23:59", "score": 53, "height": 6, "articles": 30, "confidence": 23, "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -11, "score_change_display": "-2"}, {"tone": "neutral", "delta": 2, "label": "21 Aug 23:59", "score": 52, "height": 4, "articles": 30, "confidence": 22, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "24 Aug 23:59", "score": 52, "height": 4, "articles": 24, "confidence": 19, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "25 Aug 23:59", "score": 51, "height": 4, "articles": 25, "confidence": 19, "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "-1"}, {"tone": "neutral", "delta": 6, "label": "26 Aug 23:59", "score": 56, "height": 12, "articles": 26, "confidence": 32, "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score_change": 5, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 13, "score_change_display": "+5"}, {"tone": "neutral", "delta": 6, "label": "27 Aug 23:59", "score": 56, "height": 12, "articles": 25, "confidence": 31, "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 5, "label": "28 Aug 23:59", "score": 55, "height": 10, "articles": 27, "confidence": 33, "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 3, "label": "01 Sep 23:59", "score": 53, "height": 6, "articles": 26, "confidence": 31, "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-2"}, {"tone": "neutral", "delta": 2, "label": "05 Sep 23:59", "score": 52, "height": 4, "articles": 20, "confidence": 26, "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "06 Sep 23:59", "score": 52, "height": 4, "articles": 21, "confidence": 25, "short_label": "06 Sep", "collected_at": "2026-09-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "07 Sep 23:59", "score": 52, "height": 4, "articles": 22, "confidence": 24, "short_label": "07 Sep", "collected_at": "2026-09-07T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "10 Sep 23:59", "score": 51, "height": 4, "articles": 20, "confidence": 22, "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "13 Sep 23:59", "score": 51, "height": 4, "articles": 18, "confidence": 20, "short_label": "13 Sep", "collected_at": "2026-09-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "17 Sep 23:59", "score": 52, "height": 4, "articles": 24, "confidence": 29, "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+1"}, {"tone": "neutral", "delta": 2, "label": "18 Sep 23:59", "score": 52, "height": 4, "articles": 26, "confidence": 26, "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "21 Sep 23:59", "score": 52, "height": 4, "articles": 25, "confidence": 25, "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "22 Sep 23:59", "score": 52, "height": 4, "articles": 28, "confidence": 28, "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "23 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 27, "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "24 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 24, "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "27 Sep 23:59", "score": 51, "height": 4, "articles": 33, "confidence": 19, "short_label": "27 Sep", "collected_at": "2026-09-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "28 Sep 23:59", "score": 51, "height": 4, "articles": 34, "confidence": 18, "short_label": "28 Sep", "collected_at": "2026-09-28T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "01 Oct 23:59", "score": 50, "height": 4, "articles": 34, "confidence": 16, "short_label": "01 Oct", "collected_at": "2026-10-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 0, "label": "07 Oct 01:50", "score": 50, "height": 4, "articles": 30, "confidence": 14, "short_label": "07 Oct", "collected_at": "2026-10-07T01:50:44.180392+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v11", "live_version": "evidence-v11", "comparable_to_live": true, "reconstructed": true, "observations": 43, "span_label": "103 days", "first_score": 50, "latest_score": 50, "net_change": 0, "net_change_display": "+0", "direction": "Broadly stable", "high_score": 56, "low_score": 46, "latest_confidence": 14, "confidence_change": 14, "latest_articles": 30, "article_change": 29, "latest_label": "07 Oct 01:50", "latest_evidence_label": "Provisional", "chart_rows": [{"tone": "neutral", "delta": 0, "label": "25 Jun 23:59", "score": 50, "height": 4, "articles": 1, "confidence": 0, "short_label": "25 Jun", "collected_at": "2026-06-25T23:59:59.999999+00:00", "score_change": null, "reconstructed": true, "score_version": "evidence-v11", "article_change": null, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": null, "score_change_display": "Start", "x": 42.0, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "01 Jul 23:59", "score": 50, "height": 4, "articles": 2, "confidence": 0, "short_label": "01 Jul", "collected_at": "2026-07-01T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 63.8, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "10 Jul 23:59", "score": 50, "height": 4, "articles": 3, "confidence": 0, "short_label": "10 Jul", "collected_at": "2026-07-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 85.6, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "20 Jul 23:59", "score": 50, "height": 4, "articles": 4, "confidence": 0, "short_label": "20 Jul", "collected_at": "2026-07-20T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Insufficient", "evidence_status": "insufficient", "confidence_change": 0, "score_change_display": "+0", "x": 107.4, "y": 135.0}, {"tone": "neutral", "delta": 1, "label": "21 Jul 23:59", "score": 51, "height": 4, "articles": 6, "confidence": 29, "short_label": "21 Jul", "collected_at": "2026-07-21T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 29, "score_change_display": "+1", "x": 129.2, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "22 Jul 23:59", "score": 51, "height": 4, "articles": 7, "confidence": 25, "short_label": "22 Jul", "collected_at": "2026-07-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -4, "score_change_display": "+0", "x": 151.0, "y": 133.2}, {"tone": "neutral", "delta": 5, "label": "23 Jul 23:59", "score": 55, "height": 10, "articles": 11, "confidence": 35, "short_label": "23 Jul", "collected_at": "2026-07-23T23:59:59.999999+00:00", "score_change": 4, "reconstructed": true, "score_version": "evidence-v11", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 10, "score_change_display": "+4", "x": 172.9, "y": 125.9}, {"tone": "neutral", "delta": 4, "label": "24 Jul 23:59", "score": 54, "height": 8, "articles": 14, "confidence": 32, "short_label": "24 Jul", "collected_at": "2026-07-24T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1", "x": 194.7, "y": 127.7}, {"tone": "neutral", "delta": 3, "label": "28 Jul 23:59", "score": 53, "height": 6, "articles": 15, "confidence": 26, "short_label": "28 Jul", "collected_at": "2026-07-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "-1", "x": 216.5, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "29 Jul 23:59", "score": 52, "height": 4, "articles": 16, "confidence": 24, "short_label": "29 Jul", "collected_at": "2026-07-29T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 238.3, "y": 131.4}, {"tone": "neutral", "delta": 4, "label": "31 Jul 23:59", "score": 54, "height": 8, "articles": 17, "confidence": 29, "short_label": "31 Jul", "collected_at": "2026-07-31T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 5, "score_change_display": "+2", "x": 260.1, "y": 127.7}, {"tone": "neutral", "delta": 3, "label": "04 Aug 23:59", "score": 53, "height": 6, "articles": 18, "confidence": 28, "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1", "x": 281.9, "y": 129.5}, {"tone": "neutral", "delta": 3, "label": "05 Aug 23:59", "score": 53, "height": 6, "articles": 21, "confidence": 26, "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 303.7, "y": 129.5}, {"tone": "neutral", "delta": -4, "label": "06 Aug 23:59", "score": 46, "height": 8, "articles": 25, "confidence": 34, "short_label": "06 Aug", "collected_at": "2026-08-06T23:59:59.999999+00:00", "score_change": -7, "reconstructed": true, "score_version": "evidence-v11", "article_change": 4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 8, "score_change_display": "-7", "x": 325.5, "y": 142.3}, {"tone": "neutral", "delta": -2, "label": "07 Aug 23:59", "score": 48, "height": 4, "articles": 26, "confidence": 35, "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 1, "score_change_display": "+2", "x": 347.3, "y": 138.6}, {"tone": "neutral", "delta": -2, "label": "09 Aug 23:59", "score": 48, "height": 4, "articles": 26, "confidence": 29, "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -6, "score_change_display": "+0", "x": 369.1, "y": 138.6}, {"tone": "neutral", "delta": -2, "label": "10 Aug 23:59", "score": 48, "height": 4, "articles": 27, "confidence": 27, "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 391.0, "y": 138.6}, {"tone": "neutral", "delta": 4, "label": "11 Aug 23:59", "score": 54, "height": 8, "articles": 29, "confidence": 34, "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score_change": 6, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 7, "score_change_display": "+6", "x": 412.8, "y": 127.7}, {"tone": "neutral", "delta": 6, "label": "12 Aug 23:59", "score": 56, "height": 12, "articles": 31, "confidence": 37, "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score_change": 2, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+2", "x": 434.6, "y": 124.1}, {"tone": "neutral", "delta": 5, "label": "13 Aug 23:59", "score": 55, "height": 10, "articles": 32, "confidence": 34, "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "-1", "x": 456.4, "y": 125.9}, {"tone": "neutral", "delta": 3, "label": "20 Aug 23:59", "score": 53, "height": 6, "articles": 30, "confidence": 23, "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -11, "score_change_display": "-2", "x": 478.2, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "21 Aug 23:59", "score": 52, "height": 4, "articles": 30, "confidence": 22, "short_label": "21 Aug", "collected_at": "2026-08-21T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "-1", "x": 500.0, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "24 Aug 23:59", "score": 52, "height": 4, "articles": 24, "confidence": 19, "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0", "x": 521.8, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "25 Aug 23:59", "score": 51, "height": 4, "articles": 25, "confidence": 19, "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 0, "score_change_display": "-1", "x": 543.6, "y": 133.2}, {"tone": "neutral", "delta": 6, "label": "26 Aug 23:59", "score": 56, "height": 12, "articles": 26, "confidence": 32, "short_label": "26 Aug", "collected_at": "2026-08-26T23:59:59.999999+00:00", "score_change": 5, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 13, "score_change_display": "+5", "x": 565.4, "y": 124.1}, {"tone": "neutral", "delta": 6, "label": "27 Aug 23:59", "score": 56, "height": 12, "articles": 25, "confidence": 31, "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 587.2, "y": 124.1}, {"tone": "neutral", "delta": 5, "label": "28 Aug 23:59", "score": 55, "height": 10, "articles": 27, "confidence": 33, "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 2, "score_change_display": "-1", "x": 609.0, "y": 125.9}, {"tone": "neutral", "delta": 3, "label": "01 Sep 23:59", "score": 53, "height": 6, "articles": 26, "confidence": 31, "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score_change": -2, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-2", "x": 630.9, "y": 129.5}, {"tone": "neutral", "delta": 2, "label": "05 Sep 23:59", "score": 52, "height": 4, "articles": 20, "confidence": 26, "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1", "x": 652.7, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "06 Sep 23:59", "score": 52, "height": 4, "articles": 21, "confidence": 25, "short_label": "06 Sep", "collected_at": "2026-09-06T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 674.5, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "07 Sep 23:59", "score": 52, "height": 4, "articles": 22, "confidence": 24, "short_label": "07 Sep", "collected_at": "2026-09-07T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 696.3, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "10 Sep 23:59", "score": 51, "height": 4, "articles": 20, "confidence": 22, "short_label": "10 Sep", "collected_at": "2026-09-10T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 718.1, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "13 Sep 23:59", "score": 51, "height": 4, "articles": 18, "confidence": 20, "short_label": "13 Sep", "collected_at": "2026-09-13T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 739.9, "y": 133.2}, {"tone": "neutral", "delta": 2, "label": "17 Sep 23:59", "score": 52, "height": 4, "articles": 24, "confidence": 29, "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score_change": 1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 6, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 9, "score_change_display": "+1", "x": 761.7, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "18 Sep 23:59", "score": 52, "height": 4, "articles": 26, "confidence": 26, "short_label": "18 Sep", "collected_at": "2026-09-18T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 2, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0", "x": 783.5, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "21 Sep 23:59", "score": 52, "height": 4, "articles": 25, "confidence": 25, "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 805.3, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "22 Sep 23:59", "score": 52, "height": 4, "articles": 28, "confidence": 28, "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+0", "x": 827.1, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "23 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 27, "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 849.0, "y": 131.4}, {"tone": "neutral", "delta": 2, "label": "24 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 24, "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0", "x": 870.8, "y": 131.4}, {"tone": "neutral", "delta": 1, "label": "27 Sep 23:59", "score": 51, "height": 4, "articles": 33, "confidence": 19, "short_label": "27 Sep", "collected_at": "2026-09-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1", "x": 892.6, "y": 133.2}, {"tone": "neutral", "delta": 1, "label": "28 Sep 23:59", "score": 51, "height": 4, "articles": 34, "confidence": 18, "short_label": "28 Sep", "collected_at": "2026-09-28T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0", "x": 914.4, "y": 133.2}, {"tone": "neutral", "delta": 0, "label": "01 Oct 23:59", "score": 50, "height": 4, "articles": 34, "confidence": 16, "short_label": "01 Oct", "collected_at": "2026-10-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1", "x": 936.2, "y": 135.0}, {"tone": "neutral", "delta": 0, "label": "07 Oct 01:50", "score": 50, "height": 4, "articles": 30, "confidence": 14, "short_label": "07 Oct", "collected_at": "2026-10-07T01:50:44.180392+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0", "x": 958.0, "y": 135.0}], "chart_points": "42.0,135.0 63.8,135.0 85.6,135.0 107.4,135.0 129.2,133.2 151.0,133.2 172.9,125.9 194.7,127.7 216.5,129.5 238.3,131.4 260.1,127.7 281.9,129.5 303.7,129.5 325.5,142.3 347.3,138.6 369.1,138.6 391.0,138.6 412.8,127.7 434.6,124.1 456.4,125.9 478.2,129.5 500.0,131.4 521.8,131.4 543.6,133.2 565.4,124.1 587.2,124.1 609.0,125.9 630.9,129.5 652.7,131.4 674.5,131.4 696.3,131.4 718.1,133.2 739.9,133.2 761.7,131.4 783.5,131.4 805.3,131.4 827.1,131.4 849.0,131.4 870.8,131.4 892.6,133.2 914.4,133.2 936.2,135.0 958.0,135.0", "changes": [{"tone": "neutral", "delta": 0, "label": "07 Oct 01:50", "score": 50, "height": 4, "articles": 30, "confidence": 14, "short_label": "07 Oct", "collected_at": "2026-10-07T01:50:44.180392+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "+0"}, {"tone": "neutral", "delta": 0, "label": "01 Oct 23:59", "score": 50, "height": 4, "articles": 34, "confidence": 16, "short_label": "01 Oct", "collected_at": "2026-10-01T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -2, "score_change_display": "-1"}, {"tone": "neutral", "delta": 1, "label": "28 Sep 23:59", "score": 51, "height": 4, "articles": 34, "confidence": 18, "short_label": "28 Sep", "collected_at": "2026-09-28T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 1, "label": "27 Sep 23:59", "score": 51, "height": 4, "articles": 33, "confidence": 19, "short_label": "27 Sep", "collected_at": "2026-09-27T23:59:59.999999+00:00", "score_change": -1, "reconstructed": true, "score_version": "evidence-v11", "article_change": -4, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -5, "score_change_display": "-1"}, {"tone": "neutral", "delta": 2, "label": "24 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 24, "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 0, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "23 Sep 23:59", "score": 52, "height": 4, "articles": 37, "confidence": 27, "short_label": "23 Sep", "collected_at": "2026-09-23T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 9, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "22 Sep 23:59", "score": 52, "height": 4, "articles": 28, "confidence": 28, "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": 3, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": 3, "score_change_display": "+0"}, {"tone": "neutral", "delta": 2, "label": "21 Sep 23:59", "score": 52, "height": 4, "articles": 25, "confidence": 25, "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score_change": 0, "reconstructed": true, "score_version": "evidence-v11", "article_change": -1, "evidence_label": "Provisional", "evidence_status": "provisional", "confidence_change": -1, "score_change_display": "+0"}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}